The study examines how administering drugs to suppress the immune system can preserve lung function and potentially prevent progression in mild stages of interstitial lung disease (ILD), which is a life-threatening complication of scleroderma. The findings suggest a promising window of opportunity to treat ILD early on, when it is mild, to prevent its progression to a life-threatening complication. With further study, this treatment approach could save lives for those with scleroderma.

Read more on the Arthritis Society’s website.

Publication
Hoa S, Bernatsky S, Steele RJ, Baron M, Hudson M. Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. Rheumatology (Oxford). 2019 Sep 19. pii: kez407.

 

January 8 2020